A Study of RG1662 in Adults and Adolescents With Down Syndrome (CLEMATIS)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02024789 |
Recruitment Status :
Completed
First Posted : December 31, 2013
Last Update Posted : October 25, 2017
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Down Syndrome | Drug: Placebo Drug: RG1662 | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 173 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double (Participant, Investigator) |
Primary Purpose: | Treatment |
Official Title: | A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY OF THE EFFICACY, SAFETY AND TOLERABILITY OF RG1662 IN ADULTS AND ADOLESCENTS WITH DOWN SYNDROME (CLEMATIS) |
Actual Study Start Date : | May 5, 2014 |
Actual Primary Completion Date : | May 4, 2016 |
Actual Study Completion Date : | May 4, 2016 |

Arm | Intervention/treatment |
---|---|
Placebo Comparator: Placebo |
Drug: Placebo
Orally twice daily, 26 weeks |
Experimental: RG1662 120 mg bid |
Drug: RG1662
120 mg (80 mg for subjects 12 and 13 years of age) orally twice daily, 26 weeks |
Experimental: RG1662 240 mg bid |
Drug: RG1662
240 mg (160 mg for subjects 12 and 13 years of age) orally twice daily, 26 weeks |
- Cognition as assessed by the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) sub-tests [ Time Frame: 26 weeks ]
- Adaptive behavior as assessed by the Vineland Adaptive Behavior Scales-II (VABS-II) standard scores [ Time Frame: 26 weeks ]
- Clinical global impression as assessed by Clinician Rated Global Improvement (CGI-I) scale [ Time Frame: 26 weeks ]
- Incidence of abnormal ECG changes [ Time Frame: 26 weeks ]
- Abnormal ECG changes in adolescents as compared to baseline [ Time Frame: from baseline to Week 26 ]
- Safety: Incidence of adverse events [ Time Frame: approximately 32 weeks ]
- Incidence of abnormal blood pressure [ Time Frame: 26 weeks ]
- RG1662 plasma concentrations [ Time Frame: 26 weeks ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 12 Years to 30 Years (Child, Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Individuals aged 12-30 years of age inclusive
- Clinical diagnosis of Down syndrome (trisomy 21) confirmed by chromosomal analysis (karyotyping)
- Males, or non-pregnant, non-lactating females. For females of childbearing potential, strict contraceptive prevention is required.
- Body-mass Index (BMI) 18-42 and 15-30 kg/m2 inclusive for adults and adolescents respectively
- Ability to complete the Clinical Evaluation of Language Fundamentals (CELF)-preschool 2 word classes task
- Subjects must have a parent, or other reliable caregiver who agrees to accompany the subject to all clinic visits, provide information about the subject as required by the protocol, and ensure compliance with the medication schedule
- Study participants must have sufficient language, vision and hearing to participate in study evaluations, as judged clinically by investigator
Exclusion Criteria:
- Subjects with a current DSM 5 diagnosis of any primary psychiatric diagnosis (including ASD or MDD)
- Subjects with a history of infantile spasms, of West syndrome, Lennox-Gastaut syndrome, Early Infantile Epileptic Encephalopathy or any treatment-refractory epilepsy associated with cognitive or developmental regression, of severe head trauma or CNS infections (e.g. meningitis)
- Subjects with a known or suspected clinical seizure event of any type within 24 months prior to screening
- Clinically relevant ECG abnormalities at screening or baseline; QTcF above 450 ms; personal or family history (first degree relatives) of congenital long QT syndrome
- Inadequate renal or hepatic function

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02024789

Study Director: | Clinical Trials | Hoffmann-La Roche |
Responsible Party: | Hoffmann-La Roche |
ClinicalTrials.gov Identifier: | NCT02024789 |
Other Study ID Numbers: |
BP27832 2013-001263-23 ( EudraCT Number ) |
First Posted: | December 31, 2013 Key Record Dates |
Last Update Posted: | October 25, 2017 |
Last Verified: | October 2017 |
Down Syndrome Syndrome Disease Pathologic Processes Intellectual Disability Neurobehavioral Manifestations |
Neurologic Manifestations Nervous System Diseases Abnormalities, Multiple Congenital Abnormalities Chromosome Disorders Genetic Diseases, Inborn |